Category: Pα+ - Psychedelic Alpha

Read more about the article From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

Post published:July 7, 2025
Post category:Interviews Pα+

Read more about the article Oregon Psilocybin Services Tracker: Q1 2025

Oregon Psilocybin Services Tracker: Q1 2025

Post published:July 4, 2025
Post category:Analysis Pα+

Read more about the article Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Post published:July 1, 2025
Post category:Analysis News Pα+

Read more about the article Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Post published:July 1, 2025
Post category:Interviews Pα+

Read more about the article Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

Post published:June 28, 2025
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #202: Psychedelics Access ‘Within 12 Months’, RFK Jr. Says; Psychedelics in Washington; Lykos’ New CEO, CMO; New Zealand’s First Psilocybin Prescriber; Judge Recommends Schedule I Placement for DOI and DOC

Pα+ Psychedelic Bulletin #202: Psychedelics Access ‘Within 12 Months’, RFK Jr. Says; Psychedelics in Washington; Lykos’ New CEO, CMO; New Zealand’s First Psilocybin Prescriber; Judge Recommends Schedule I Placement for DOI and DOC

Post published:June 27, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin Results

Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin Results

Post published:June 25, 2025
Post category:Analysis News Pα+

Read more about the article Australia’s Largest Private Health Insurer Commits $10M to Fund MDMA Therapy for PTSD in First-of-its-Kind Program

Australia’s Largest Private Health Insurer Commits $10M to Fund MDMA Therapy for PTSD in First-of-its-Kind Program

Post published:June 18, 2025
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #201: Dispatches from Prague and London; Texas Becomes Leader in Ibogaine Research as Governor Signs $50M Match-Funding Bill; High-Dose LSD Shows Potential in Depression, But Findings Are Fragile

Pα+ Psychedelic Bulletin #201: Dispatches from Prague and London; Texas Becomes Leader in Ibogaine Research as Governor Signs $50M Match-Funding Bill; High-Dose LSD Shows Potential in Depression, But Findings Are Fragile

Post published:June 13, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article May 2025 Psychedelic Patent Update: Gilgamesh Broadens Moat Around Lead Candidate Following Positive Phase 2a Readout; Lykos Publishes Further Continuation Applications; Reconnect Joins Crowded 5-MeO-DMT Patent Landscape

May 2025 Psychedelic Patent Update: Gilgamesh Broadens Moat Around Lead Candidate Following Positive Phase 2a Readout; Lykos Publishes Further Continuation Applications; Reconnect Joins Crowded 5-MeO-DMT Patent Landscape

Post published:June 12, 2025
Post category:Psychedelic Patent Analysis Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.